| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | APR-1051 advanced solid tumors (including uterine serous carcinoma; cyclin E–overexpressing, platinum-resistant ovarian cancer; HPV-positive head and neck cancer; colorectal cancer) | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 1 data readout example | APR-1051 advanced solid tumors (including uterine serous carcinoma; cyclin E–overexpressing, platinum-resistant ovarian cancer; HPV-positive head and neck cancer; colorectal cancer) | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 1 data readout example | APR-1051 advanced solid tumors (including uterine serous carcinoma; cyclin E–overexpressing, platinum-resistant ovarian cancer; HPV-positive head and neck cancer; colorectal cancer) | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Aprea Therapeutics, Inc.
$0.81
+0.16 (+25.75%)
D 39Pipeline Score Undervalued Pharma · Clinical
Market Cap
10.14 M
EPS
-0.98
P/E Ratio
-
Value Trade
20.38 K
19.82 %
Week
28.89 %
1 Month
-11.52 %
3 Month
0.66 %
6 Month
-98.91 %
5 Year
-99.69 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.80 M
52 Week Range
0.55 - 1.69
% held by Insiders
9.13 %
% held by Institutions
39.02 %
Enterprise Value
-31.10 M
Total Shares
12.59 M
Short %
0.36 %
Float Shares
8.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aprea Therapeutics, Inc.
370Total events
13Upcoming
62Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T3Enrollment Milestone
Subscribe to view catalyst details
Event history 2
TBD
▲Enrollment UpdateAPR-1051Trial
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-01 | APR-1051 (WEE1 kinase inhibitor) | phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-01 | APR-1051 (WEE1 kinase inhibitor) | phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-01 | APR-1051 (WEE1 kinase inhibitor) | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D39
Pipeline Score $122M
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored15.0x
rNPV / MCap Top 61%
Micro Cap (rank 365 of 933)
Percentile RankAprea Therapeutics, Inc. faces pipeline headwinds (39/100), with $570M risk-adjusted pipeline value, led by APR-246 in Hematologic Neoplasms (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APR-246+ azacitidine Small molecule | MDS | Phase 3 | NCT03745716 | 68% | $190M | COMPLETED | 154 | - | - | Jan 14, 2022 | - | Mar 18, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
APR-1051 | uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) | Phase 1 | 2026-08-12 | early single-agent activity for APR-1051, including partial responses and disease stabilization Read More | Aprea Therapeutics Announces Second Quarter 2026 Financial Results Read More | |
APR-1051 | uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) | Phase 1 | 2026-08-12 | early single-agent activity for APR-1051, including partial responses and disease stabilization Read More | Aprea Therapeutics Announces Second Quarter 2026 Financial Results Read More | |
APR-1051 | uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) | Phase 1 | 2026-08-12 | early single-agent activity for APR-1051, including partial responses and disease stabilization Read More | Aprea Therapeutics Announces Second Quarter 2026 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APRE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
APRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
APREAprea Therapeutics Announces Second Quarter 2026 Financial Results
Aprea Therapeutics reported positive developments in its Phase 1 ACESOT-1051 trial for APR-1051, an oral WEE1 inhibitor. The company is expanding enrollment and advancing dose escalation, with early data showing clinical activity. Financial results indicate a cash position of $41.2 million, though operating losses have increased. Aprea plans to evaluate APR-1051 in multiple cancer types and report further data in Q4 2026.
Read more →APREAprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Aprea Therapeutics has provided an update on its Phase 1 ACESOT-1051 trial for the WEE1 inhibitor APR-1051, indicating accelerated enrollment and plans for combination therapies. The next clinical data update is expected in Q4 2026, with an expansion of clinical sites from three to ten. The company aims to broaden its development strategy, targeting specific cancer types with significant unmet needs.
Read more →APRE▼ -8.6%on this news
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor APR-1051 at ASCO 2026, highlighting early clinical activity with partial responses and stable disease in patients with advanced solid tumors. The study demonstrated manageable tolerability, with adverse events primarily being mild. Enrollment is expanding into uterine serous carcinoma and platinum-resistant ovarian cancer, with completion of dose escalation expected by Q2 2027.
Read more →APREAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Aprea Therapeutics reported its Q1 2026 financial results, highlighting progress in the ACESOT-1051 trial of APR-1051, a WEE1 inhibitor. The trial has shown two partial responses and good tolerability among patients. The company closed a $30 million private placement to support further development and expansion of patient enrollment. Additional data will be presented at the ASCO 2026 Annual Meeting.
Read more →APRE▼ -7.5%on this news
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
Aprea Therapeutics announced that an abstract regarding early results from its Phase 1 trial of the WEE1 inhibitor APR-1051 has been accepted for presentation at the 2026 ASCO Annual Meeting. This trial, referred to as ACESOT-1051, focuses on patients with advanced solid tumors. The presentation is scheduled for May 30, 2026, with the session highlighting developmental therapeutics and molecularly targeted agents. Aprea is known for its targeted therapies, striving to improve cancer treatment outcomes while minimizing effects on healthy cells.
Read more →APRE▼ -7.7%on this news
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is wel
Aprea Therapeutics has announced the successful closing of an oversubscribed $30 million private placement financing. The company plans to utilize these funds to support the ongoing development of APR-1051, specifically focusing on selected patient populations for whom the WEE1 mechanism is advantageous. The financing reflects strong interest from prominent investors and aims to enhance clinical studies, particularly targeting uterine serous carcinoma and platinum-resistant ovarian cancer. This funding is expected to notably progress Aprea's research efforts in targeted therapies.
Read more →APRE▲ +8.2%on this newsshared move
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Aprea Therapeutics announced an oversubscribed private placement financing expected to yield approximately $30 million. The financing was led by Soleus Capital and includes participation from other investors. The funds will be utilized for general corporate purposes and research and development, particularly in ongoing clinical trials for targeted therapies in oncology. The offering is anticipated to close by March 31, 2026.
Read more →APRE▲ +8.2%on this newsshared move
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Aprea Therapeutics has reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during the ongoing Phase 1 ACESOT-1051 trial of APR-1051. The trial aims to evaluate the safety and preliminary anti-tumor activity of this WEE1 kinase inhibitor. Early data suggests promising anti-tumor activity without significant toxicity, with further updates expected in 2026.
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial
Aprea Therapeutics has reported its fourth-quarter and full-year financial results for 2025, demonstrating a focus on advancing targeted cancer therapies. Notably, the ongoing ACESOT-1051 trial of APR-1051 showed early proof-of-concept, with two patients achieving partial responses. Despite the progress, the company continues to face significant financial losses and uncertainties regarding future clinical trial outcomes. Aprea's financial situation has improved with recent private placements, which provide better flexibility for upcoming challenges.
Read more →APRE▲ +21.3%on this news· ran to +36% by day 1
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics announced promising preliminary results from its Phase 1 ACESOT-1051 trial of the WEE1 inhibitor APR-1051, reporting a second unconfirmed partial response in a patient with advanced endometrial cancer. The patient showed a 50% reduction in target lesions and a significant drop in CA-125 levels. The trial continues to enroll patients, focusing on those with specific genetic mutations.
Read more →APREAprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aprea Therapeutics will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. The presentation will be led by Dr. Oren Gilad, the company's President and CEO. Aprea focuses on developing therapies that target cancer-specific vulnerabilities while minimizing harm to healthy cells.
Read more →APREAprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
Aprea Therapeutics has expanded its global patent portfolio with new patents granted in Australia and Japan, ensuring exclusivity for its WEE1 and ATR programs until 2045. The lead candidate, APR-1051, is currently in Phase 1 trials, demonstrating early clinical promise. This strategic move positions Aprea for long-term growth and value creation in the oncology space.
Read more →APRE▼ -6.8%on this news
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Aprea Therapeutics has appointed Dr. Eugene Kennedy as Chief Medical Advisor following promising early clinical results for its WEE1 inhibitor, APR-1051. Dr. Kennedy brings over 20 years of experience in oncology drug development, which Aprea believes will enhance its clinical leadership. The company aims to optimize dose and patient selection in its ongoing clinical trials.
Read more →APRE▼ -22.8%on this news
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
Aprea Therapeutics announced early clinical proof-of-concept for its WEE1 inhibitor APR-1051 in the ongoing Phase 1 ACESOT-1051 trial. A patient with PPP2R1A-mutated uterine serous carcinoma exhibited a 50% reduction in tumor size and a significant decrease in CA-125 levels. The trial continues to evaluate higher dose cohorts, indicating potential for broader therapeutic applications.
Read more →APRE▼ -22.8%on this newsshared move
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics announced a $5.6 million private placement to support its clinical studies. The offering includes 6,288,857 shares of common stock and warrants, priced at $0.89 each. The funds will be used for general corporate purposes and research. The closing is expected around January 30, 2026, pending customary conditions.
Read more →APRExA9; 2026 Aprea Therapeutics, Inc. All Rights Reserved Precision Oncology Through Synthetic Lethality Transforming DDR Inhibition into Patient Benefit January 2026 2 © 2026 Aprea Therapeutics, Inc. All Rights Reserv
Aprea Therapeutics is progressing with its WEE1 inhibitor program, APR-1051, following positive preclinical results and collaborations. The warrants have been issued for additional capital which could support the company's ongoing clinical trials. Aprea is also investigating potential combination therapies with existing cancer treatments to expand the use of its lead candidate. The firm highlights the importance of successful enrollment and completion of its clinical trials for long-term viability.
Read more →APREAprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Aprea Therapeutics, Inc. CEO Oren Gilad recently communicated the company's developments and future prospects in a letter to shareholders. The letter highlights progress in their clinical programs, specifically the promising results from APR-1051, a WEE1 inhibitor, showing anti-tumor activity. Aprea also reached a significant financing milestone that ensures operational funding through 2027. Nonetheless, the company has paused enrollment in certain studies to align their resources with strategic priorities as they explore combination therapies.
Read more →APRE▼ -10.8%on this news
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules Financing from new and existing healthcare focused investors The proceeds are expected to extend the Company's cash runw
Aprea Therapeutics has announced a $3.1 million private placement of shares and warrants to enhance its financial position, expected to fund operations into Q1 2027. This financing, involving both new and existing healthcare-focused investors, will support the company's clinical development efforts. The offering will close around December 10, 2025, and aims to capitalize on anticipated inflection points in its cancer treatment programs. Aprea's therapies target specific cancer cell vulnerabilities while limiting harm to healthy cells.
Read more →APREAprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
Aprea Therapeutics reported its third-quarter 2025 financial results, highlighting progress in its clinical programs for WEE1 and ATR inhibitors. The company noted promising early data from the APR-1051 trial, with three out of four patients showing stable disease. Aprea is also exploring combination strategies for ATR-119 as it moves towards Phase 2 development.
Read more →APRE▼ -7.9%on this news
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
Aprea Therapeutics provided an update on the Phase 1 ACESOT-1051 trial for APR-1051, a WEE1 kinase inhibitor. The results indicated that 75% of patients at the 100 mg dose level achieved stable disease. The data will be presented at the AACR-NCI-EORTC conference, highlighting the potential of APR-1051 in treating advanced solid tumors.
Read more →APREAprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Aprea Therapeutics has determined a recommended Phase 2 dose of 1,100 mg for ATRN-119, its oral ATR inhibitor, as part of the ongoing ABOYA-119 study. The company is considering further development in combination therapies, particularly with DNA-damaging agents. While enrollment in monotherapy arms is paused, current patients will continue treatment without interruption. A poster on ATRN-119 will be presented at an upcoming conference.
Read more →APREAprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics announced that two of its clinical program abstracts have been accepted for poster presentation at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics. The conference is scheduled for October 22-26, 2025, in Boston, Massachusetts. Aprea is focused on developing cancer therapies that target specific vulnerabilities in cancer cells while sparing healthy tissues.
Read more →APREPrecision Oncology Through Synthetic Lethality Transforming DDR Inhibition into Patient Benefit September 2025 2 © 2025 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information con
Aprea Therapeutics is advancing its clinical development of the WEE1 inhibitor APR-1051, which has shown promise in treating HPV+ head and neck squamous cell carcinoma. The patient receiving APR-1051 continues treatment with manageable toxicity, suggesting potential for effective patient outcomes. Aprea is also working on patent applications for various cancer treatment methodologies and maintains a focus on enhancing patient benefits through its therapeutic innovations.
Read more →APREAprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
Aprea Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The presentation is scheduled for September 9 at 3:30 PM ET. Aprea focuses on developing cancer therapies that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells.
Read more →APREAprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stabl
Aprea Therapeutics reported its second quarter 2025 financial results, highlighting early signs of disease control in the Phase 1 ACESOT-1051 trial with the WEE1 inhibitor APR-1051. The company noted the achievement of stable disease in three patients and expressed optimism about the potential of its drug development programs. Financial results showed a net loss of $3.24 million, contributing to ongoing operating losses, raising concerns about its cash reserves. The firm's collaborations and pipeline emphasize targeting cancer vulnerabilities, which may lead to innovative treatment options.
Read more →APRE▲ +10.1%on this news
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Aprea Therapeutics has reported positive early-stage clinical data for APR-1051, a next-generation WEE1 inhibitor, in treating HPV+ head and neck squamous cell carcinoma (HNSCC). The initial Phase 1 clinical update shows early disease control in the first patient treated. The findings, supported by preclinical data from MD Anderson Cancer Center, suggest APR-1051's potential as a single agent and in combination with immunotherapies.
Read more →APREAprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recom
Aprea Therapeutics reported its first quarter 2025 financial results, highlighting promising clinical developments for its ATR inhibitor, ATRN-119, which exhibited early anti-tumor activity in patients. In the ongoing ABOYA-119 trial, tumor shrinkage was observed in several patients treated with ATRN-119 at a dose below the recommended Phase 2 dose. The company also provided updates on its WEE1 inhibitor, APR-1051, and reported a cash position that supports operations well into mid-2026. Overall, these results emphasize Aprea's commitment to addressing critical needs in cancer therapy.
Read more →APREAprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
Aprea Therapeutics has announced the dosing of the first patient with HPV+ head and neck squamous cell carcinoma in its ongoing ACESOT-1051 clinical trial. This trial evaluates the efficacy of APR-1051, a WEE1 inhibitor, in patients with advanced solid tumors. Open label data from the study is expected in the second half of 2025, with a focus on optimizing dosing and assessing safety.
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label saf
Aprea Therapeutics reported its financial results for the fourth quarter and full year 2024 while updating on its clinical trials. The company is enrolling patients in the ACESOT-1051 trial for its WEE1 kinase inhibitor, APR-1051, now entering Cohort 5. They expect to report efficacy data from this trial in H2 2025. Alongside financial updates, Aprea emphasizes the progress of its ATR inhibitor, ATRN-119, indicating a strategic advancement in their cancer treatment pipeline. The company concluded 2024 with a cash position of $22.8 million, enabling ongoing operations amidst significant R&D expenses.
Read more →APRE▲ +9.9%on this news
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
Aprea Therapeutics has signed a Material Transfer Agreement with MD Anderson Cancer Center to explore the potential of its WEE1 kinase inhibitor, APR-1051, in treating head and neck squamous cell carcinoma (HNSCC). The collaboration aims to conduct preclinical experiments focusing on both HPV+ and HPV- tumor types. Notably, the research is expected to investigate the combination of APR-1051 with immune checkpoint inhibitors. This partnership reflects Aprea's dedication to advancing innovative cancer treatments through strategic academic alliances.
Read more →APREAprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics DOYLESTOWN, PA
Aprea Therapeutics has announced an evolution of its patent portfolio focused on DNA Damage Response therapeutics. This includes protections for its ATR and WEE1 inhibitor programs, which are in clinical trials for advanced solid tumors. The firm aims to leverage its intellectual property to develop innovative cancer treatments that target cell vulnerabilities while limiting damage to healthy tissues. The announcement comes with expectations of extended exclusivity through potential patent approvals.
Read more →APRE▼ -6.4%on this news
Precision Oncology Through Synthetic Lethality January 2025 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forwar
Aprea Therapeutics is focusing on precision oncology through the development of ATR and WEE1 inhibitors, with multiple patent applications filed. The company is conducting clinical trials aimed at assessing the safety and efficacy of these compounds for treating various cancers. However, Aprea faces challenges, including the need for further financing and risks associated with clinical development outcomes, as demonstrated by the discontinuation of similar compounds due to tolerability issues. The outcome of ongoing studies will be critical for the company's future success in this competitive field.
Read more →APREAprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Aprea Therapeutics has announced the first patient dosed in the ongoing ABOYA-119 clinical trial of ATRN-119, now utilizing a twice daily dosing regimen. This strategic amendment aims to optimize the therapeutic activity of the drug and improve clinical outcomes for patients with advanced solid tumors. The trial primarily focuses on evaluating the tolerability and pharmacokinetics of ATRN-119, with expectations for a Phase 1 readout in the second half of 2025. The company believes that this proactive approach may enhance the drug’s competitive positioning and shareholder value.
Read more →APREAprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated wi
Aprea Therapeutics reported its financial results for Q3 2024, highlighting substantial progress in its clinical pipeline. The preliminary findings from the Phase 1 ACESOT-1051 trial of the WEE1 inhibitor, APR-1051, are promising, showing well tolerance without unexpected toxicities. The company has $26.2 million in cash reserves, which extends their operational runway for at least a year. However, Aprea reported a net loss of $3.78 million for the quarter, with increasing operating expenses.
Read more →APRE▼ -6.7%on this news
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051
Aprea Therapeutics recently presented preliminary findings on its oral WEE1 inhibitor, APR-1051, at a major oncology conference. The Phase 1 ACESOT-1051 trial is evaluating the drug's safety and efficacy in patients with advanced solid tumors. According to the preliminary results, APR-1051 has been found to be safe, with no significant side effects reported so far. The ongoing study is currently enrolling participants at multiple sites across the United States.
Read more →APREAprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
Aprea Therapeutics, Inc. is set to participate in the Maxim Healthcare Virtual Summit from October 15 to 17, 2024. Dr. Oren Gilad, President and CEO, will deliver two presentations focused on precision oncology. This event highlights the company's strategic focus on advancing its clinical programs and engaging with the investment community. Aprea Therapeutics aims to leverage this platform to discuss its ongoing research and future initiatives in the arena of synthetic lethality.
Read more →APREAprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Aprea Therapeutics has announced that four abstracts will be presented at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The presentations will highlight the company's progress in developing DNA damage response inhibitors, including their clinical-stage candidates APR-1051 and ATRN-119. Aprea's CEO expressed enthusiasm about showcasing their work to the international oncology community at this significant event. The abstracts include safety and preliminary efficacy studies as well as the development of new therapeutic candidates.
Read more →APREAprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development DOYLESTOWN, PA
Aprea Therapeutics has appointed Philippe Pultar, MD, as Senior Medical Advisor, focusing on the development of APR-1051, its potential leading WEE1 inhibitor. Dr. Pultar brings extensive experience from his previous role at Zentalis Pharmaceuticals. The company is currently conducting the Phase 1 ACESOT-1051 study to evaluate APR-1051's safety and efficacy in advanced solid tumors. Aprea aims to provide additional updates on the clinical study's progress by the end of 2024. This strategic addition is part of Aprea's commitment to enhancing its research and precision oncology capabilities.
Read more →APREAprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Aprea Therapeutics, a clinical-stage biopharmaceutical company, announced participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. CEO Oren Gilad will present via webcast and engage in one-on-one meetings with investors to discuss the company's developments. This event aims to provide insights into Aprea's ongoing efforts in precision oncology, focusing on their lead program ATRN-119 among other initiatives.
Read more →APRE▲ +6.2%on this news
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
Aprea Therapeutics, Inc. announced that its CEO, Oren Gilad, will present at the Life Sciences Investor Forum on September 19, 2024. The presentation will include updates on the company's ongoing clinical trials, including the evaluation of APR-1051 and ATRN-119. Investors will have the opportunity to engage in a live Q&A, enhancing the interaction between the company and potential investors. A recording of the presentation will be available for those unable to attend live.
Read more →APREAprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Oren Gilad, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9-11, 2024, in New York, NY. The company is focused on precision oncology and will highlight its lead program, ATRN-119, among other updates. Attendees will have access to the presentation on demand, and there will also be opportunities for one-on-one meetings with institutional investors.
Read more →APREAprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight
Aprea Therapeutics announced its financial results for Q2 2024, highlighting the initiation of the ACESOT-1051 Phase 1 trial for APR-1051, a WEE1 kinase inhibitor. The trial has begun enrolling patients, with no observed myelosuppression in the initial group. The company reported $28.7 million in cash, extending its financial runway into Q4 2025. However, Aprea also noted a net loss of $3.47 million for the quarter, raising some concerns regarding its long-term financial viability.
Read more →APREAprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Aprea Therapeutics is set to host a virtual Key Opinion Leader (KOL) event on June 24, 2024, focusing on APR-1051, their advanced oral WEE1 inhibitor. The event will feature discussions by prominent experts on the drug's design and preclinical results, highlighting its potential as a best-in-class option in oncology. The company recently initiated a Phase 1 trial of APR-1051 targeting patients with Cyclin E overexpression, aiming to address significant unmet medical needs in cancer treatment.
Read more →APREAprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 c
Aprea Therapeutics has announced that it has dosed the first patient in its ACESOT-1051 Phase 1 trial for the oral WEE1 inhibitor, APR-1051. This study aims to evaluate APR-1051 as a monotherapy treatment option for patients with advanced solid tumors who have significant unmet medical need. The trial's design focuses on patients with specific genetic alterations, with the goal of assessing safety and potential efficacy. Aprea plans to provide a clinical update by the end of 2024.
Read more →APREAprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics has received endorsement from the Safety Review Committee to start dosing ATRN-119 at 800 mg once daily in the ongoing ABOYA-119 clinical trial. This follows a review of safety and pharmacokinetic data from an earlier dose cohort. The trial has progressed with 17 patients enrolled across initial cohorts, demonstrating that ATRN-119 is safe and well tolerated with indications of potential clinical benefits. Initial efficacy data from the trial is anticipated in the second half of 2024.
Read more →APRE▲ +5.4%on this news
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to ini
Aprea Therapeutics reported its financial results for the first quarter of 2024, highlighting significant advancements including the FDA's clearance of the IND for its oral WEE1 inhibitor, APR-1051, which is anticipated to enter Phase 1 clinical trials in June 2024. The company showcased progress with its ATR inhibitor ATRN-119, expected to complete dose escalation by the end of the year. Financially, Aprea reported $32.4 million in cash and equivalents, reflecting a robust position to support its clinical programs. Additionally, the company had notable presentations at the recent AACR Annual Meeting.
Read more →APREAprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
Aprea Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference set for May 14-15 in New York. The company's management will be accessible for one-on-one meetings, emphasizing their focus on investor engagement. Aprea is dedicated to precision oncology, particularly through synthetic lethality, and has made significant advancements with its lead program ATRN-119 and recent FDA clearance for its WEE1 inhibitor APR-1051.
Read more →APREAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aprea Therapeutics has appointed Dr. Nadeem Q. Mirza as Chief Medical Officer, effective May 1, 2024. Dr. Mirza, who has been a consultant for the company since February 2023, will lead the development of Aprea's clinical pipeline. His extensive background in oncology and drug development positions him well for this role, especially as Aprea advances its promising asset APR-1051. The company has also granted stock options and restricted stock units to Dr. Mirza as part of his employment offer, demonstrating commitment to his role in the strategic expansion of Aprea's clinical programs.
Read more →APREAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 Pre-clinical findings underscore the potential of A
Aprea Therapeutics announced four poster presentations at the AACR Annual Meeting 2024, detailing the potential of its next-generation WEE1 inhibitor, APR-1051, and its macrocyclic ATR inhibitor, ATRN-119. The pre-clinical data for APR-1051 suggests its effectiveness in treating Cyclin E-overexpressing cancers. Furthermore, ATRN-119 continues to show a favorable safety profile in its ongoing Phase 1/2a study, with promising early clinical benefits. Both projects represent significant steps forward in Aprea's oncology pipeline.
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially gener
Aprea Therapeutics has reported its financial results for Q4 and the full year of 2023, showcasing significant progress in its synthetic lethality cancer therapies. The company's lead candidate, ATRN-119, is set to complete dose escalation in 2024, with human efficacy data anticipated later in the year. Additionally, FDA clearance for the oral WEE1 inhibitor APR-1051 was obtained, and a Phase 1 clinical trial is planned for H1 2024. Despite leveraging a recent $16 million financing, Aprea faces ongoing financial losses and high operating expenses.
Read more →APRE▼ -5%on this news· ran to -26% by day 3
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
Aprea Therapeutics has received FDA clearance for its Investigational New Drug application for APR-1051, a next-generation WEE1 kinase inhibitor targeting Cyclin E overexpressing cancers. The company plans to initiate a Phase 1 clinical trial named ACESOT-1051, focusing on evaluating the safety and efficacy of APR-1051. Initial patient enrollment is expected in the first half of 2024, with updates anticipated in Q4 2024. Preclinical studies have shown promising results, suggesting the drug may have a better safety profile compared to other WEE1 inhibitors. Aprea aims to leverage its innovative approach to precision oncology through this development.
Read more →APRE▼ -5%on this news· ran to -26% by day 3
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfr
Aprea Therapeutics has announced a private placement financing of up to $34 million, led by Sphera Healthcare. The financing includes $16 million in upfront gross proceeds and potential additional funds from warrant exercises. The capital raised will be utilized for clinical development of the company's WEE1 inhibitor, APR-1051, and ongoing patient enrollment for its ATR inhibitor, ATRN-119. This financing aims to bolster Aprea’s efforts in precision oncology and enhance its market position.
Read more →APREAprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Aprea Therapeutics, a biopharmaceutical company, announced the acceptance of four abstracts for poster presentations at the American Association of Cancer Research Annual Meeting 2024, scheduled for April 5 to 10 in San Diego. The presentations will focus on their investigational drugs ATRN-119 and APR-1051, which target cancer through synthetic lethality. Key topics include clinical trials for WEE1 and ATR inhibitors. This event is a significant opportunity for Aprea to highlight advancements in precision oncology.
Read more →APRE▲ +12%on this news
Precision Oncology Through Synthetic Lethality February 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forwa
Aprea Therapeutics is focusing on synthetic lethality in oncology through its ATR and WEE1 inhibitors. The company has filed international applications for these compounds and continues to advance its clinical trials with a focus on cancer treatment. However, the ongoing reliance on additional financing may limit their operational flexibility. Additionally, identified risks include uncertain clinical trial outcomes and adverse effects observed in current studies.
Read more →APRE▲ +12%on this news
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
Aprea Therapeutics has submitted an Investigational New Drug (IND) application to the FDA for APR-1051, a novel WEE1 kinase inhibitor. This submission is considered an important milestone for the company, as it aims to initiate clinical trials in the first half of 2024. APR-1051 has shown strong preclinical promise, differentiating itself from current WEE1 inhibitors with its unique molecular structure and potentially favorable pharmacokinetic properties. However, the company is awaiting FDA approval, which remains a critical factor for the continuation of its clinical development.
Read more →APREAprea Therapeutics to Present at DDR Inhibitors Summit 2024
Aprea Therapeutics announced that Dr. Oren Gilad, the President and CEO, will present at the 7th DDR Inhibitors Summit in Boston from January 30 to February 1, 2024. The presentation is titled 'Prioritizing Patient Selection for Combination Studies to Optimize Treatments' and will cover important advancements in cancer treatment through the DDR pathway. Aprea is also guiding towards FDA clearance of its IND for its oral WEE1 inhibitor. This event illustrates Aprea's commitment to progress in precision oncology.
Read more →APREAprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 DOYLESTOWN, Pa.
Aprea Therapeutics provided an update on its corporate activities and development plans for 2024, emphasizing progress in its pipeline of DNA Damage Response anti-cancer agents. Key developments include ongoing enrollment in the Phase 1 trial of ATRN-119 and the imminent submission of an IND for the WEE1 inhibitor APR-1051. The company anticipates presenting detailed findings from the Phase 1 study at a medical meeting in the first half of 2024 and will participate in a corporate access event to discuss its strategy with investors.
Read more →APREAprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update DOYLESTOWN, PA
Aprea Therapeutics reported its financial results for Q3 2023, highlighting advancements in its clinical programs. The company shared promising initial data from its ATRN-119 study, demonstrating a favorable safety profile and potential efficacy in tumor reduction. Furthermore, Aprea plans to submit an IND for its WEE1 inhibitor, ATRN-1051, before the end of 2023. Despite these positive developments, the company continues to face financial losses and a growing deficit, which may impact its future operations.
Read more →APREAprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Aprea Therapeutics announced a Key Opinion Leader (KOL) event scheduled for October 31, 2023, focusing on synthetic lethality and DNA damage response in oncology. Leading researchers, Dr. Fiona Simpkins and Dr. Timothy A. Yap, will present insights into current treatment landscapes and investigational drugs for advanced solid tumors. The event will cover Aprea’s key therapeutic programs, including ATRN-119 and the upcoming WEE1 inhibitor ATRN-1051, which is set for IND submission by year-end. The session will conclude with a live Q&A segment and will be available for replay on the company’s investor relations website.
Read more →APREAprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio DOYLESTOWN, Pa.
Aprea Therapeutics presented initial clinical data for its ATR inhibitor, ATRN-119, and its WEE1 inhibitor, ATRN-1051, at the AACR-NCI-EORTC conference. The data showcased ATRN-119's tolerability and manageable toxicity, with no dose-limiting toxicities reported. Additionally, ATRN-1051 demonstrated selectivity with low off-target activity, suggesting a potential for effective anti-cancer combinations. The company is currently enrolling patients for ongoing trials, with plans for dose expansion anticipated in Q2 2024.
Read more →APREPrecision Oncology Through Synthetic Lethality October 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section
Aprea Therapeutics' ATRN-119, an oral ATR inhibitor, demonstrated its potential as a preferred treatment option due to reduced toxicity in trials. The drug's performance in a comparative study showed better outcomes than a competitor ATR inhibitor, with manageable side effects in terms of body weight changes. However, Aprea acknowledges that results could diverge from expectations due to various risks, including financial dependence and clinical trial uncertainties.
Read more →APREAprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics announced its participation in the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, where it will present two key posters. The posters will focus on ATRN-119, a small-molecule ATR inhibitor currently in Phase 1/2a trials, and ATRN-1051, an oral WEE1 inhibitor expected to file for IND submission by the end of 2023. These presentations aim to showcase the potential effectiveness and tolerability of these candidates as cancer treatments. Senior executives from the company will also attend the conference.
Read more →APREAprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
Aprea Therapeutics has announced promising preclinical data for its WEE1 inhibitor, ATRN-1051, aimed at treating ovarian cancer. The data indicate that ATRN-1051 has a favorable safety and efficacy profile compared to existing WEE1 inhibitors. The company plans to submit an Investigational New Drug (IND) application by the end of 2023 and will present further data at an upcoming scientific conference. Additionally, the findings suggest that ATRN-1051's selective inhibition may address the limitations that other WEE1 inhibitors face, particularly in relation to off-target effects.
Read more →APREPrecision Oncology Through Synthetic Lethality September 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Secti
Aprea Therapeutics has reported promising findings regarding its investigational ATR inhibitor, ATRN-119, which has demonstrated potential as a best-in-class treatment with a favorable toxicity profile compared to competitors. In a recent study, a dog undergoing treatment with ATRN-119 maintained normal levels of blood cells and experienced negligible changes in body weight. However, Aprea has cautioned that forward-looking statements regarding the product's development are subject to various risks, including the dependency on future financing and the inherent uncertainties of clinical trials.
Read more →APREAprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aprea Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Oren Gilad, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference in New York from September 11-13, 2023. The presentation will include details about the company's focus on precision oncology and its lead program ATRN-119. Management will also be available for one-on-one meetings with attendees, potentially enhancing investor engagement. The event will be accessible virtually and the presentation will be available for replay afterward.
Read more →APREAprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
Aprea Therapeutics has announced the appointment of Dr. Jean-Pierre Bizzari to its Board of Directors, replacing Mr. Christian Schade who has stepped down. Dr. Bizzari, previously Group Head of Clinical Development Oncology at Celgene, brings significant experience in oncology drug development. Dr. Richard Peters, who has been an independent Director since 2020, has been named Chairman of the Board. This leadership change is expected to guide Aprea towards impactful milestones in their work on synthetic lethality and DNA damage repair therapeutics.
Read more →APREAprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations DOYLESTOWN, PA
Aprea Therapeutics has reported its financial results for the second quarter of 2023, highlighting progress in its clinical programs, particularly with ATRN-119, an ATR inhibitor. The company anticipates initial data from its lead study by the fourth quarter of 2023 and is on track for IND submission of ATRN-1051, a WEE1 inhibitor, by year-end. Despite a net loss reported for the quarter, Aprea maintains a solid cash runway into late 2024, allowing it to support its ongoing research and development efforts.
Read more →APREAprea Therapeutics to Present at Maxim Virtual Healthcare Conference
Aprea Therapeutics, Inc. announced that its CEO, Oren Gilad, will participate in a fireside chat at the Maxim Virtual Healthcare Conference from June 20 to June 22, 2023. This event will showcase Aprea's work in developing cancer therapeutics targeting DNA damage response pathways. A live webcast of the presentation will be available on the company's website, along with an archived replay afterward. The company is currently advancing multiple clinical-stage drug candidates, including ATRN-119 and ATRN-1051.
Read more →APREAprea Therapeutics to Present at BIO International Convention
Aprea Therapeutics, Inc. announced that CEO Oren Gilad will present a corporate overview at the BIO International Convention from June 5-8, 2023. The focus will be on their lead clinical candidate, ATRN-119, which is currently in a Phase 1/2a trial for advanced solid tumors. The presentation underscores Aprea's commitment to developing innovative cancer therapeutics targeting DNA damage response pathways.
Read more →APRE▼ -7.3%on this news
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations DOYLESTOWN, PA
Aprea Therapeutics, Inc. reported a strong financial position for Q1 2023, highlighting a significant cash runway into the third quarter of 2024 and progress in clinical trials for its cancer therapeutics. The company is advancing its ATRN-119 and WEE1 inhibitor programs, with an IND filing anticipated by the end of 2023. However, Aprea reported a net loss of $4.38 million this quarter, with ongoing high research and development costs and inherent uncertainties in the clinical trial outcomes.
Read more →APREAprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
Aprea Therapeutics has appointed Dr. Gabriela Gruia to its Board of Directors, effective May 5, 2023. Dr. Gruia brings over 25 years of experience in clinical and regulatory affairs, which the company believes will be invaluable in advancing its pipeline of synthetic lethality inhibitors, particularly the lead candidate ATRN-119. Her previous leadership roles at major pharmaceutical companies reflect her capability in enhancing drug development strategies, aligning with Aprea's mission to address cancer treatment needs.
Read more →APREAprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors DOYLESTOWN, PA, May 8 2023 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical
Aprea Therapeutics has appointed Dr. Gabriela Gruia, M.D. to its Board of Directors, effective May 5, 2023. Dr. Gruia brings over 25 years of experience in clinical development and regulatory affairs, which Aprea anticipates will enhance its efforts in advancing its cancer therapeutic pipeline. The company is focusing on synthetic lethality-based treatments and is particularly keen on the progress of its lead candidate, ATRN-119, currently in clinical trials. This strategic appointment comes as Aprea positions itself for future growth and success in addressing patient needs in oncology.
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations DOYLESTOWN, PA
Aprea Therapeutics reported its financial results for the fourth quarter and full year of 2022, highlighting significant developments in its clinical programs. The company initiated a Phase 1/2a clinical trial for its ATR inhibitor, ATRN-119, and secured $5.5 million through a public offering. Despite these advances, Aprea reported a considerable increase in its net loss over the year, alongside a notable reduction in current assets. The appointment of John Hamill as CFO is expected to support the company’s ongoing efforts in developing synthetic lethality-based cancer therapeutics.
Read more →APREAprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
Aprea Therapeutics announced that an abstract related to its preclinical programs, ATRN-119 and ATRN-W1051, has been selected for a poster presentation at the AACR 2023 Annual Meeting. The presentation is scheduled for April 19, 2023, in Orlando, Florida. The company is focused on developing innovative therapies targeting DNA damage response pathways, with their lead program being ATRN-119, aimed at solid tumor indications. The event highlights Aprea's commitment to advancing cancer therapeutics.
Read more →APRE▼ -5.3%on this news
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
Aprea Therapeutics, Inc. announced that its CEO, Oren Gilad, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference taking place online from March 14-16, 2023. This presentation will include information about the company's focus on synthetic lethality-based therapies for cancer. The event aims to showcase Aprea's research efforts and provide an opportunity for one-on-one meetings with investors.
Read more →APREAprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement DOYLESTOWN, PA
Aprea Therapeutics, Inc. has announced that it has regained compliance with the Nasdaq minimum bid price requirement, ensuring its continued listing on the stock market. The company attributes this achievement to recent financing supported by esteemed institutions, which has bolstered its financial position. Aprea continues to focus on the development of its clinical asset, ATRN-119, and pre-clinical asset ATRN-W1051, enhancing its focus on cancer therapeutics targeting DNA damage response pathways.
Read more →APREAprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
Aprea Therapeutics has successfully closed a public offering, selling 1,050,000 shares of its common stock at $5.25 each, raising about $5.5 million. The company plans to use the proceeds to advance its clinical asset, ATRN-119, and its pre-clinical asset, ATRN-W1051, along with general corporate purposes. This stock offering was made under an effective shelf registration statement filed with the SEC. Additionally, there is a 30-day option for underwriters to purchase more shares.
Read more →APRE▼ -20%on this newsshared move
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
Aprea Therapeutics has announced the pricing of an underwritten public offering of 1,050,000 shares at $5.25 per share, aiming to raise approximately $5.5 million. The proceeds will be allocated towards advancing its clinical asset ATRN-119, pre-clinical asset ATRN-W1051, and general corporate purposes. The public offering follows an effective registration statement filed with the SEC, and Maxim Group LLC is serving as the sole book-running manager for this offering.
Read more →APREAprea Therapeutics Announces Proposed Public Offering of Common Stock DOYLESTOWN, Pa.
Aprea Therapeutics, a biopharmaceutical company focused on cancer therapeutics, has announced a proposed public offering of its common stock. The offering will be underwritten by Maxim Group LLC and is currently subject to market conditions. Aprea intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares. The company emphasizes that there are no assurances regarding the timing or completion of this offering, adding a layer of risk to the potential investors.
Read more →APREAprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
Aprea Therapeutics announced that it has received a Phase II SBIR Award from the National Cancer Institute for its research on DNA damage response inhibitors aimed at treating high-grade serous ovarian cancer. The award, totaling up to $1,996,571 over two years, will support the company's development efforts including a first-in-human trial of ATRN-119 and a WEE1 inhibitor. Research will focus on evaluating the effectiveness and tolerability of these inhibitors using various cancer models, possibly leading to new treatments for patients with this aggressive cancer type.
Read more →APRE▼ -13.5%on this news· ran to -27% by day 3shared move
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split DOYLESTOWN, PA
Aprea Therapeutics, Inc. has announced a one-for-twenty reverse stock split to help regain compliance with the Nasdaq Global Select Market listing requirements. This action reduces the outstanding shares from approximately 53.6 million to about 2.68 million without altering the overall ownership percentages of existing stockholders. The reverse stock split became effective on February 10, 2023, and trading under the new shares began on February 13, 2023.
Read more →APRE▼ -8.8%on this news· ran to -32% by day 3shared move
Precision Oncology through Synthetic Lethality February 2023 Forward - Looking Statements Certain information contained in this presentation includes "forward - looking statements", within the meaning of Section 27A of t
The article discusses the role of precision oncology through synthetic lethality, reflecting on developments and forward-looking statements as of February 2023. It highlights the concept of using synthetic lethality in a precision oncology context, though no specific advancements or results are detailed. The information presented implies ongoing explorations in the field, but lacks specific data or breakthroughs related to the topic.
Read more →APREAprea Therapeutics Appoints John Hamill as Chief Financial Officer DOYLESTOWN, PA
Aprea Therapeutics has announced the appointment of John Hamill as Chief Financial Officer, who brings over 30 years of finance and accounting expertise. His joining coincides with the company's advancement in clinical trials for its ATR inhibitor. The outgoing CFO, Scott Coiante, will remain until the end of March 2023 to facilitate a smooth transition. Hamill expressed enthusiasm about working with the team to enhance the pipeline and pursue future growth.
Read more →APRExA9; 2023 Aprea Therapeutics, Inc. All Rights Reserved. 1 January 24 - 26 , 2023 | Boston, MA | ddr - inhibitors - summit.com 2 Adding On to Monotherapy: Combining DDR Inhibitors January 2023 Forward - Looking Statements
Aprea Therapeutics, Inc. has warned about the uncertainties and risks associated with its product candidates. The company emphasizes the reliance on additional financing and the challenges posed by potential overlapping toxicity with other agents. Furthermore, Aprea's history is limited regarding the assets acquired from Atrin Pharmaceuticals Inc., leading to uncertainties in the development trajectory. These statements underscore the significant risks inherent in the clinical trial process.
Read more →APRE▼ -7.6%on this news
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
Aprea Therapeutics, Inc. announced its participation in the 6th Annual DNA Damage and Response (DDR) Inhibitors Summit in Boston from January 24 to 26, 2023. CEO Oren Gilad will take part in discussions on validating new therapeutic targets for clinical trials and addressing toxicity issues related to DDR inhibitors. Additionally, Scientific Consultant Eric Brown will present on the company's proprietary discovery platform, Repli-Biom, aimed at identifying biomarkers related to DDR inhibitor efficacy. This represents an important opportunity for Aprea to showcase its advances in cancer therapeutics.
Read more →APRE▲ +12%on this news· ran to +22% by day 3
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
Aprea Therapeutics announced the dosing of the first patient in its Phase 1/2a clinical trial for ATRN-119, an oral ATR inhibitor aimed at treating advanced solid tumors with DDR mutations. This multi-center, open-label trial will evaluate the drug's tolerability, pharmacokinetics, and efficacy. Preclinical studies have shown ATRN-119's potential in inhibiting tumor growth while exhibiting lower toxicity than existing therapies. Company executives expressed optimism about the drug's potential to address significant medical needs in cancer therapy.
Read more →APREPrecision Oncology through Synthetic Lethality January 2023 Forward - Looking Statements Certain information contained in this presentation includes "forward - looking statements", within the meaning of Section 27A of t
The article discusses precision oncology through synthetic lethality, highlighting developments as of January 2023. While it introduces the concept of synthetic lethality within precision oncology, it does not provide specific details about advancements or outcomes. The mention of 'forward-looking statements' suggests a focus on future potential rather than current results. Overall, the content remains general without significant positive or negative news.
Read more →APREAprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, MA
Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, MA, November 9, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-bas
Read more →APREAprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the abstract titled “ATRN-W
Read more →APREAprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad Ph.D, President
Read more →APREAprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, MA, August 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel syn
Read more →APREAprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
BOSTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Ch
Read more →APRE▼ -29.7%on this news
Precision Oncology Through Synthetic Lethality May 2022 Forward - Looking Statements Certain information contained in this presentation includes " forward - looking statements " , within the meaning of Section 27 A of th
Precision Oncology Through Synthetic Lethality May 2022 Precision Oncology Through Synthetic Lethality May 2022
Read more →APRE▼ -19.1%on this news· ran to -46% by day 3shared move
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results BOSTON, MA
Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results BOSTON, MA, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therape
Read more →APRE▲ +5.5%on this news· ran to +21% by day 1
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations BOSTON, MA
Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reac
Read more →APRE▼ -6.9%on this news
J.P. Morgan 40 th Annual Healthcare Conference January 2022 Forward - Looking Statements Certain information contained in this presentation includes "forward - looking statements", within the meaning of Section 27A of th
J.P. Morgan 40 th Annual Healthcare Conference January 2022 J.P. Morgan 40 th Annual Healthcare Conference January 2022
Read more →APREAprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, C
Read more →APRE▼ -10.8%on this news· ran to -23% by day 3
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
60% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant Median overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and c
Read more →APREAprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies BOSTON, MA
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies BOSTON, MA, December 9, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer ther
Read more →APREAprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, November 8, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel can
Read more →APREAprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that investigators will present
Read more →APREAprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the European Socie
Read more →APREAprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation o
Read more →APREAprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, August 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel can
Read more →APREAprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Adm
Read more →APREAprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs BOSTON, MA
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid BOSTON, MA, August 5, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor
Read more →APRE▼ -5.5%on this news· ran to -17% by day 3
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
58% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics
Read more →APREAprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53,
Read more →APREAprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice Pr
Read more →APREAprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairm
Read more →APREAprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, May 6, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer t
Read more →APREAprea Therapeutics to Host Virtual R&D Day on April 22, 2021
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtua
Read more →APREAprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Dru
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the t
Read more →APREAprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, C
Read more →APREJ.P. Morgan 39 th Annual Healthcare Conference January 2021 Forward - Looking Statements Certain information contained in this presentation includes "forward - looking statements", within the meaning of Section 27A of th
J.P. Morgan 39 th Annual Healthcare Conference January 2021 Forward - Looking Statements Certain information contained in this presentation includes "forward - looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Read more →APREAprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) - The trial failed to meet its primary endpoint of complete remission (CR) rate -
Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic MA, December 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel c
Read more →APREAprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug
Read more →APREAprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, C
Read more →APREAprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations BOSTON, MA, November 5, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel can
Read more →APREAprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with pr
Read more →APREAprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com
Read more →APREAprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S. Food an
Read more →APREAprea Therapeutics Appoints Michael A. Kelly to Board of Directors BOSTON, MA.
Therapeutics Appoints Michael A. Kelly to Board of Directors BOSTON, MA., September 29, 2020 (GLOBE NEWSWIRE) - Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate m
Read more →APREAprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes BOSTON, MA.
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes BOSTON, MA., September 18, 2020 (GLOBE NEWSWIRE) - Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializ
Read more →APREAprea Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Company is scheduled
Read more →APREAprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations BOSTON, MA, August 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel can
Read more →APREAprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
Commenced expansion cohort in combination with venetoclax and azacitidine Added cohort to be activated in combination with azacitidine BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commer
Read more →APREAprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors BOSTON, MA.
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors BOSTON, MA., June 29, 2020 (GLOBE NEWSWIRE) - Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel c
Read more →APREAprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS in patients receiving 3 or more cycles of therapy with 9.7 months duration of follow
Read more →APREAprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
Topline data expected by year-end 2020 Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeut
Read more →APREAprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Presid
Read more →APREAprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations BOSTON, MA
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations BOSTON, MA, May 15, 2020 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer t
Read more →APREAprea Therapeutics Launches New Corporate Website - www.aprea.com
BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, rede
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update BOSTON, MA
Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update MA, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics
Read more →APREAprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Gr
Read more →APREAprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that the U.S. Food and Drug Admi
Read more →APREAprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that Christian S. Schade, Presid
Read more →APREAprea Therapeutics, Inc. January 2020 J.P. Morgan 38 th Annual Healthcare Conference 2 2020 Aprea Therapeutics, Inc. Forward - Looking Statements Certain information contained in this press release includes "forward - lo
2020 Aprea Therapeutics, Inc. January 2020 J.P. Morgan 38 th Annual Healthcare Conference 2 2020 Aprea Therapeutics, Inc. Forward - Looking Statements Certain information contained in this press release includes "forward - looking statements", within the meaning of Section 27A o
Read more →APREAprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
74% ORR, 66% CR rate in 24 evaluable MDS patients Median duration of follow-up is 6.4 months BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that
Read more →APREAprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients 8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients 52% of evaluable MDS patients discontinued treatment for stem cell transplant BOSTON, Dec. 09, 2019 (GLOBE
Read more →APREAprea Therapeutics Reports Third Quarter 2019 Financial Results BOSTON, MA.
Aprea Therapeutics Reports Third Quarter 2019 Financial Results BOSTON, MA., Nov. 14, 2019 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppr
Read more →APREAprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that it will present updated dat
Read more →APREAprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the closing of its initial publ
Read more →APREAprea Therapeutics Announces Pricing of Initial Public Offering
BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the pricing of its initial public offering of
Read more →APREAprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco
Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S. Schade, President & Chief Executive Officer, is scheduled to present a company update
Read more →APREAprea AB Names Christian S. Schade President & Chief Executive Officer
“I am delighted to welcome Chris to Aprea,” said Bernd R. Seizinger, M.D., Ph.D., Chairman of the Board of Directors. “He is an accomplished biopharmaceutical executive with proven experience leading companies through times of change and growth. He has successfully executed major
Read more →APREAprea announces positive data from a clinical Phase I/II study with APR-246 in patients with advanced cancers
STOCKHOLM – September 18, 2012. Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology. Based on the positive data, Aprea is planni
Read more →APREAprea reports completion of the Phase I/II safety study with APR‐246 in cancer patients
Stockholm, Sweden – February 23, 2011. Aprea has conducted a Phase I/II dose‐escalating safety study with APR‐246 in patients with refractory hematological malignancies or prostate cancer. The results show that the compound is safe at predicted therapeutic plasma levels. "The re
Read more →Competitive Position
How APRE ranks across every disease it competes inCompetitive Position is a premium feature
See how APRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial